Pre-operative High-dose-rate Brachytherapy in Early-stage Cervical Cancer: Long-term Single-center Results

Overview

Journal J Contemp Brachytherapy

Date 2022 Mar 2

PMID 35233234

Authors

Sylwia Kellas-Sleczka

Piotr Wojcieszek

Marta Szlag

Magdalena Stankiewicz

Agnieszka Cholewka

Maciej Sleczka

Agnieszka Badora-Rybicka

Piotr Lelek

Agnieszka Pruefer

Tomasz Krzysztofiak

Zofia Kolosza

Marek Fijalkowski

Affiliations

Soon will be listed here.

Abstract

Purpose: The aim of the study was to report the outcomes of pre-operative high-dose-rate brachytherapy (pHDR-BT), followed by hysterectomy in patients with early cervical cancer.

Material And Methods: From January, 1998 to December, 2003, 113 women with IB1, IB2, and IIA1 cervical cancer (according to International Federation of Gynecology and Obstetrics [FIGO] 2018) were treated with pHDR-BT, and 6 to 8 weeks later followed by radical hysterectomy. Patients found to have positive lymph nodes, residual cervical cancer, involved parametria, or lymphovascular space invasion (LVSI) received post-operative adjuvant therapy.

Results: Post-operatively, 81.4% of patients had a complete response to pHDR-BT in the cervix, and 18.6% had residual cervical cancer. Failures occurred in 11/113 (9.7%) patients (all were stage IIA1), with pelvic recurrences in 5/113 (4.4%) and distant metastasis (DM) in 6/113 (5.3%). The 5- and 10-year disease-free survival (DFS) rates were 100% for IB1 and IB2, and 86.4% and 81.3% for IIA1, respectively. Lymph node involvement and/or residual cervical cancer correlated with worse DFS. Two vesicovaginal fistulas were observed (one in a patient treated only with pHDR-BT and one in a woman, who underwent adjuvant external-beam radiotherapy [EBRT]). Two rectovaginal fistulas and one case of proctitis were observed in patients treated with adjuvant EBRT.

Conclusions: pHDR-BT in early cervical cancer is well-tolerated and effective in sterilizing tumor cells in the cervix. The growing number of publications in this area may help define an optimal therapeutic scheme, but randomized trials are required to determine the best candidates for this treatment modality.In our opinion, cervical cancer patients with FIGO stage IIA1 are not good candidates for pHDR-BT, and could be given this treatment only after rigorous selection, including assessment with state-of-the-art imaging, due to higher probability of treatment failure.

References

Beskow C, Granath F, Frankendal B, Lewensohn R . Pathologic complete remission after preoperative intracavitary radiotherapy of cervical cancer stage Ib and IIa is a strong prognostic factor for long-term survival: analysis of the Radiumhemmet data 1989-1991. Int J Gynecol Cancer. 2002; 12(2):158-70. DOI: 10.1046/j.1525-1438.2002.01089.x. View

Hannoun-Levi J, Chand-Fouche M, Gautier M, Dejean C, Marcy M, Fouche Y . Interstitial preoperative high-dose-rate brachytherapy for early stage cervical cancer: dose-volume histogram parameters, pathologic response and early clinical outcome. Brachytherapy. 2012; 12(2):148-55. DOI: 10.1016/j.brachy.2012.04.007. View

Ngo C, Alran S, Plancher C, Fourchotte V, Petrow P, Campitelli M . Outcome in early cervical cancer following pre-operative low dose rate brachytherapy: a ten-year follow up of 257 patients treated at a single institution. Gynecol Oncol. 2011; 123(2):248-52. DOI: 10.1016/j.ygyno.2011.08.011. View

Vizkeleti J, Vereczkey I, Frohlich G, Varga S, Horvath K, Pulay T . Pathologic complete remission after preoperative high-dose-rate brachytherapy in patients with operable cervical cancer: preliminary results of a prospective randomized multicenter study. Pathol Oncol Res. 2014; 21(2):247-56. DOI: 10.1007/s12253-014-9815-5. View

Charra-Brunaud C, Harter V, Delannes M, Haie-Meder C, Quetin P, Kerr C . Impact of 3D image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France: results of the French STIC prospective study. Radiother Oncol. 2012; 103(3):305-13. DOI: 10.1016/j.radonc.2012.04.007. View

Magne N, Mancy N, Chajon E, Duvillard P, Pautier P, Castaigne D . Patterns of care and outcome in elderly cervical cancer patients: a special focus on brachytherapy. Radiother Oncol. 2008; 91(2):197-201. DOI: 10.1016/j.radonc.2008.08.011. View

Resbeut M, Alzieu C, Gonzague-Casabianca L, Badinand D, Bardou V, Cravello L . Combined brachytherapy and surgery for early carcinoma of the uterine cervix: analysis of extent of surgery on outcome. Int J Radiat Oncol Biol Phys. 2001; 50(4):873-81. DOI: 10.1016/s0360-3016(01)01602-9. View

Toita T, Kato S, Niibe Y, Ohno T, Kazumoto T, Kodaira T . Prospective multi-institutional study of definitive radiotherapy with high-dose-rate intracavitary brachytherapy in patients with nonbulky (<4-cm) stage I and II uterine cervical cancer (JAROG0401/JROSG04-2). Int J Radiat Oncol Biol Phys. 2011; 82(1):e49-56. DOI: 10.1016/j.ijrobp.2011.01.022. View

Chung H, Kang S, Cho J, Kim J, Park N, Song Y . Can preoperative MRI accurately evaluate nodal and parametrial invasion in early stage cervical cancer?. Jpn J Clin Oncol. 2007; 37(5):370-5. DOI: 10.1093/jjco/hym036. View

10.

Cibula D, Potter R, Planchamp F, Avall-Lundqvist E, Fischerova D, Haie Meder C . The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer. Radiother Oncol. 2018; 127(3):404-416. DOI: 10.1016/j.radonc.2018.03.003. View

11.

Gerbaulet A, Kunkler I, Kerr G, Haie C, Michel G, PRADE M . Combined radiotherapy and surgery: local control and complications in early carcinoma of the uterine cervix--the Villejuif experience, 1975-1984. Radiother Oncol. 1992; 23(2):66-73. DOI: 10.1016/0167-8140(92)90337-t. View

12.

Nag S, Erickson B, Thomadsen B, Orton C, Demanes J, Petereit D . The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 2000; 48(1):201-11. DOI: 10.1016/s0360-3016(00)00497-1. View

13.

Calais G, Le Floch O, Chauvet B, Reynaud-Bougnoux A, Bougnoux P . Carcinoma of the uterine cervix stage IB and early stage II. Prognostic value of the histological tumor regression after initial brachytherapy. Int J Radiat Oncol Biol Phys. 1989; 17(6):1231-5. DOI: 10.1016/0360-3016(89)90531-2. View

14.

Atlan D, Touboul E, Deniaud-Alexandre E, Lefranc J, Antoine J, Jannet D . Operable Stages IB and II cervical carcinomas: a retrospective study comparing preoperative uterovaginal brachytherapy and postoperative radiotherapy. Int J Radiat Oncol Biol Phys. 2002; 54(3):780-93. DOI: 10.1016/s0360-3016(02)02971-1. View

15.

Vu M, Yu J, Awolude O, Chuang L . Cervical cancer worldwide. Curr Probl Cancer. 2018; 42(5):457-465. DOI: 10.1016/j.currproblcancer.2018.06.003. View

16.

Escande A, Gouy S, Mazeron R, Bentivegna E, Bacorro W, Maroun P . Outcome of early stage cervical cancer patients treated according to a radiosurgical approach: Clinical results and prognostic factors. Gynecol Oncol. 2017; 144(3):541-546. DOI: 10.1016/j.ygyno.2016.12.026. View

17.

Haie-Meder C, Chargari C, Rey A, Dumas I, Morice P, Magne N . DVH parameters and outcome for patients with early-stage cervical cancer treated with preoperative MRI-based low dose rate brachytherapy followed by surgery. Radiother Oncol. 2009; 93(2):316-21. DOI: 10.1016/j.radonc.2009.05.004. View

18.

Cohen P, Jhingran A, Oaknin A, Denny L . Cervical cancer. Lancet. 2019; 393(10167):169-182. DOI: 10.1016/S0140-6736(18)32470-X. View

19.

Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P . Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet. 1997; 350(9077):535-40. DOI: 10.1016/S0140-6736(97)02250-2. View

20.

Haie-Meder C, Potter R, Van Limbergen E, Briot E, De Brabandere M, Dimopoulos J . Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol. 2005; 74(3):235-45. DOI: 10.1016/j.radonc.2004.12.015. View